NEJM Catalyst
Authors: Jessica Fields, J Raul Gutierrez, Carina Marquez, Kim Rhoads, Margot Kushel, Alicia Fernández, Gabriel Chamie, Francine Rios-Fetchko, Elizabeth Imbert, Cynthia Nagendra, Eva Pardo, Ghilamichael Andemeskel, Susana Rojas, Jon Jacobo, Valerie Tulier-Laiwa, Monique LeSarre, Gerald Green, Michael Shaw, Chris Iglesias, Jane Garcia, Aaron Ortiz, Giuliana Martinez, Andrés Aranda-Díaz, Gwendolyn Westbrook, J. Michelle Pierce, Calder Lorenz, Donna Hilliard, Isela Ford, Naveena Bobba, Kimi Watkins-Tartt, Diane Havlir, Kirsten Bibbins-Domingo
Journal of diabetes science and technology
Authors: Klonoff DC, Messler J, Valk T, Jagannathan R, Pasquel FJ, Umpierrez GE
Journal of palliative medicine
Authors: Kamal AH, Thienprayoon RM, Aldridge M, Bull J, Fazzalaro K, Meier DE, Mueller L, Rodgers PE, McKenna KA, Pantilat SZ
Public health action
Authors: Reid M
JAMA oncology
Authors: Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL, COVID-19 and Cancer Consortium
PloS one
Authors: Marcus GM, Olgin JE, Peyser ND, Vittinghoff E, Yang V, Joyce S, Avram R, Tison GH, Wen D, Butcher X, Eitel H, Pletcher MJ
Volume 218 of Issue 8 | The Journal of experimental medicine
Authors: Wilk AJ, Lee MJ, Wei B, Parks B, Pi R, Martínez-Colón GJ, Ranganath T, Zhao NQ, Taylor S, Becker W, Stanford COVID-19 Biobank, Jimenez-Morales D, Blomkalns AL, O'Hara R, Ashley EA, Nadeau KC, Yang S, Holmes S, Rabinovitch M, Rogers AJ, Greenleaf WJ, Blish CA
Our understanding of protective versus pathological immune responses to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is limited by inadequate profiling of patients at the extremes of the disease severity spectrum. Here, we performed multi-omic single-cell immune profiling of 64 COVID-19 patients across the full range of disease severity, from outpatients with mild disease to fatal cases. Our transcriptomic, epigenomic, and proteomic analyses revealed widespread dysfunction of peripheral innate immunity in severe and fatal COVID-19, including prominent hyperactivation signatures in neutrophils and NK cells. We also identified chromatin accessibility changes at NF-κB binding sites within cytokine gene loci as a potential mechanism for the striking lack of pro-inflammatory cytokine production observed in monocytes in severe and fatal COVID-19. We further demonstrated that emergency myelopoiesis is a prominent feature of fatal COVID-19. Collectively, our results reveal disease severity-associated immune phenotypes in COVID-19 and identify pathogenesis-associated pathways that are potential targets for therapeutic intervention.
View on PubMed
Diabetes technology & therapeutics
Authors: Abdulhussein FS, Chesser H, Boscardin WJ, Gitelman SE, Wong JC
Annals of internal medicine
Authors: Kuriakose S, Singh K, Pau AK, Daar E, Gandhi R, Tebas P, Evans L, Gulick RM, Lane HC, Masur H, NIH COVID-19 Treatment Guidelines Panel , Aberg JA, Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio PS, Cantrill SV, Coopersmith CM, Davis SL, Dzierba AL, Gallagher JJ, Glidden DV, Grund B, Hardy EJ, Hinkson C, Hughes BL, Johnson S, Keller MJ, Kim AY, Lennox JL, Levy MM, Li JZ, Martin GS, Naggie S, Pavia AT, Seam N, Simpson SQ, Swindells S, Tien P, Waghmare AA, Wilson KC, Yazdany J, Zachariah P, Campbell DM, Harrison C, Burgess T, Francis J, Sheikh V, Uyeki TM, Walker R, Brooks JT, Ortiz LB, Davey RT, Doepel LK, Eisinger RW, Han A, Higgs ES, Nason MC, Crew P, Lerner AM, Lund C, Worthington C
Neurology
Authors: Ayele R, Macchi ZA, Dini M, Bock M, Katz M, Pantilat SZ, Jones J, Kluger BM
